Business Wire

MA-NEURALA

8.6.2021 15:02:15 CEST | Business Wire | Press release

Share
Vision AI leader Neurala launches European Subsidiary

Today, Neurala , the leader in vision AI software, announced the launch of its European subsidiary, Neurala Europe, based in Italy. By establishing a presence in Europe, Neurala is advancing its efforts in the industrial space, bolstering on-the-ground expertise and support for its European partners, VARs and manufacturing customers as the industry increasingly prioritizes AI and automation as a part of Industry 4.0 initiatives.

Backed by Friulia S.p.A., an investment firm based in Trieste, Italy, and AddValue, an investment firm based in Milan, Italy, the new subsidiary will solidify Neurala’s global footprint and position the company as a catalyst for growth of industrial and manufacturing innovation outside of the United States. Neurala is already working with global strategic partners, including IMA Group , Antares Vision , FLIR Systems and IHI Logistics and Machinery , as well as several European systems integrators.

“As the world begins to reopen, manufacturers need cost-effective solutions that can be easily deployed and can scale to meet fluctuating consumer demands that have become the norm over the last year,” said Max Versace, CEO and co-founder of Neurala. “This new venture will enable Neurala to address that need by working closely with local partners and our team on the ground to bring vision AI onto industrial machines, cameras, and production lines.”

“In many ways, this is a homecoming for me, and for Neurala,” Versace continued. “I was born and raised in the Friuli region and have always had a connection to Italy. Naturally, I am thrilled to officially extend the bridge between Italy and the United States. With the launch of Neurala Europe, my hope is that we are able to marry Neurala’s AI expertise with Europe’s drive for industrial innovation.”

“As one of Neurala’s strategic partners, we have seen firsthand the impact of the company’s vision AI software and innovation in the industrial space,” said Dario Rea, Director of Corporate Research & Innovation, IMA Group. “The addition of a European subsidiary will put Neurala on the ground, in Europe, so that they can continue to develop relationships with local partners and distributors, making them even more competitive at a global scale, and increasing their ability to share this game-changing technology with key players in Europe and beyond.”

As part of the Neurala Europe launch, the company will hire sales, software engineering and research personnel based out of Italy, to help meet the growing demand for AI in manufacturing and visual inspections. Neurala Europe will be managed by Versace and by Daniel Glasser, Neurala’s VP of Client Operations, who will join the Board of Neurala Europe and oversee day-to-day operations.

About Neurala

Neurala is a pioneer in vision AI software. On a mission to make AI more applicable and useful in real-world applications, Neurala helps industrial companies improve their quality inspection process, with technology that dramatically reduces the time, cost and skills required to build and maintain production-quality custom vision AI solutions. Founded in 2006, Neurala’s research team invented Lifelong-DNN™ (L-DNN) technology, which lowers the data requirements for AI model development and enables continuous learning in the cloud or at the edge. Neurala is headquartered in Boston, MA with a European subsidiary in Trieste, Italy.

Follow Neurala on Twitter (@Neurala) and on Facebook , YouTube and LinkedIn .

For more information about Neurala’s AI software, request a demo .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release

New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu

Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release

Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co

SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release

The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release

Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye